Esperion Therapeutics Inc. (NASDAQ: ESPR) on November 20, 2023, started off the session at the price of $1.20, soaring 2.52% from the previous trading day. During the day, the shares moved up to $1.30 and dropped to $1.15 before settling in for the closing price of $1.19. Within the past 52 weeks, ESPR’s price has moved between $0.70 and $8.87.
Elon Musk just Triggered a BOOM in These Stocks
Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"
Click Here to Download the FREE Report.
Sponsored
Annual sales at Healthcare sector company slipped by -3.19% over the past five years. The company achieved an average annual earnings per share of 43.79%. With a float of $112.56 million, this company’s outstanding shares have now reached $113.72 million.
Let’s look at the performance matrix of the company that is accounted for 199 employees. In terms of profitability, gross margin is +63.61, operating margin of -237.83, and the pretax margin is -309.58.
Esperion Therapeutics Inc. (ESPR) Insider and Institutional Ownership
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Esperion Therapeutics Inc. is 1.02%, while institutional ownership is 77.72%. The most recent insider transaction that took place on Sep 20, was worth 924. In this transaction Chief Commercial Officer of this company sold 742 shares at a rate of $1.25, taking the stock ownership to the 68,318 shares. Before that another transaction happened on Aug 18, when Company’s Chief Commercial Officer sold 243 for $1.41, making the entire transaction worth $344. This insider now owns 69,060 shares in total.
Esperion Therapeutics Inc. (ESPR) Latest Financial update
As on 9/29/2023, Multinational firm has announced its last quarter scores, in which it reported -$0.37 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.43) by $0.06. This company achieved a net margin of -309.58. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.90% during the next five years compared to 12.80% growth over the previous five years of trading.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Esperion Therapeutics Inc. (ESPR) is currently performing well based on its current performance indicators. A quick ratio of 1.21 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.37, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -0.03 in one year’s time.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics Inc. (NASDAQ: ESPR) saw its 5-day average volume 4.04 million, a positive change from its year-to-date volume of 3.32 million. As of the previous 9 days, the stock’s Stochastic %D was 64.91%. Additionally, its Average True Range was 0.12.
During the past 100 days, Esperion Therapeutics Inc.’s (ESPR) raw stochastic average was set at 40.31%, which indicates a significant decrease from 77.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 113.05% in the past 14 days, which was higher than the 91.60% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.9847, while its 200-day Moving Average is $1.8932. Nevertheless, the first resistance level for the watch stands at $1.2967 in the near term. At $1.3733, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.4467. If the price goes on to break the first support level at $1.1467, it is likely to go to the next support level at $1.0733. The third support level lies at $0.9967 if the price breaches the second support level.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Key Stats
Market capitalization of the company is 138.74 million based on 113,718K outstanding shares. Right now, sales total 75,480 K and income totals -233,660 K. The company made 33,970 K in profit during its latest quarter, and -41,250 K in sales during its previous quarter.